# US 2013/0158016 A1 · Anesthetic association, anesthetic composition, and anesthetic medicament for veterinary use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158016 A1
- Document ID: US20130158016A1
- Status: Published application
- Kind: A1
- Application number: 13/820,514
- Filed: 2011-09-05
- Published: 2013-06-20
- Earliest claimed: 2010-09-03
- Assignees: Ouro Fino Participacoes e Empreendimentsos S/A
- Inventors: Carlos Enrique Enrique
- Web page: https://patentgrep.com/patent/US20130158016A1

## CPC

- A61K 31/5517: condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/13: Amines {(A61K31/04 takes precedence)}
- A61K 31/133: having hydroxy groups, e.g. sphingosine
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61P 23/00: Anaesthetics
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/20: Hypnotics; Sedatives
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a new association of active ingredients working as anesthetic and pre-anesthetic formulated in a composition containing anesthetics and analgesics suitable for use in surgical and pre-surgical procedures and others which require sedation, tranquilization, chemical restraint and pre-anesthetic medication. More specifically the present invention relates to a new association comprising the active ingredients ketamine, preferably the isomer S-ketamine(+), midazolam and tramadol, formulated in true solution for parenteral use. The present invention also contemplates an anesthetic drug for veterinary use for parenteral use.

## Claims

### Claim 1

An anesthetic association for veterinary use, comprising an association of at least ketamine, midazolam, and tramadol as active compounds.

### Claim 2 (depends on 1)

The association according to claim 1, wherein the active compounds midazolam and tramadol are present as a free base or as a pharmaceutically acceptable salt.

### Claim 3 (depends on 2)

The association according to claim 2, wherein the pharmaceutically acceptable salt is a maleate, a hydrochloride, or mixtures thereof.

### Claim 4 (depends on 1, 2, 3)

The association according to any one of claims 1 to 3, wherein the active compounds ketamine, midazolam, and tramadol are present in a ratio of 10:1:2, respectively.

### Claim 5 (depends on 1, 2, 3)

The association according to any one of claims 1 to 3, wherein the active compounds ketamine, midazolam, and tramadol are formulated in true solution for parenteral use.

### Claim 6 (depends on 1, 2, 3)

The association according to any one of claims 1 to 3, wherein the active compound ketamine is the isomer ketamine-(S+).

### Claim 7

An anesthetic composition for veterinary use, comprising:
as active ingredients an association of the compos ketamine, midazolam, and tramadol in an amount of at least 3% w/v;
pharmaceutically acceptable carriers; and
adjuvants.

### Claim 8 (depends on 7)

The composition according to claim 7, wherein the active ingredients ketamine, midazolam, and tramadol are present in the composition as a free base or as one or more pharmaceutically acceptable salt.

### Claim 9 (depends on 8)

The composition according to claim 8, in wherein the active ingredient ketamine is provided as hydrochloride, the active ingredient midazolam is provided as maleate and/or hydrochloride, and the active ingredient tramadol is provided as hydrochloride.

### Claim 10 (depends on 7)

A The composition according to claim 7, wherein the active ingredient ketamine is provided in proportions ranging from 2.5 to 20% w/v, the active ingredient midazolam is provided in proportions ranging from 0.25 to 2% w/v, and the active ingredient tradamol is provided in proportions ranging from 0.5 to 4% w/v.

### Claim 11 (depends on 7, 8, 9, 10)

The composition according to any one of claims 7 to 10, wherein the active compound ketamine is the isomer ketamine-(S+).

### Claim 12 (depends on 7)

The composition according to claim 7, wherein the carriers and the adjuvants are selected from the group consisting of isotonizing compounds, preservatives, antioxidants, and cosolvents.

### Claim 13 (depends on 12)

The composition according to claim 12, wherein:
the isotonizing agents are selected from the group consisting of inorganic salts of sodium (NaCl), potassium (KCl), sugars, polyalcohols, each of which has the function of the adjustment of the osmolarity of the solution to avoid plasmolysis;
the preservatives are selected from the group consisting of methylparabens, propylparaben, ethylparabens, benzyl alcohol, benzethonium chloride, benzalkonium chloride, phenols, cresols, chlorobutanols, thimerosal, and phenylmercuric compounds;
the antioxidants are selected from the group consisting of bisulfites, sulfites, metabisulfites, thiosulphates, propyl gallate, NDGA, EDTA, thioureas, monotiossorbitol, citric acid, tartaric acid, BHT, BHA, ascorbic acid, and tocopherols; and
the cosolvents are selected from the group consisting of pyrrolidones, pyrrolidone derivatives, glycols, polyglycols, polyethylene glycols, triacetin, ethers, esters of fatty acids, alcohols, glycerols, and amides.

### Claim 14

An anesthetic drug for veterinary use, comprising sufficient amounts of active ingredients so as to provide an animal with dosages of the active ingredients:
ketamine, ranging from 5.0 to 50.0 mg/kg of body weight;
midazolam ranging from 0.5 to 5.0 mg/kg of body weight; and
tramadol ranging from 1.0 to 10.0 mg/kg of body weight.

### Claim 15 (depends on 14)

The drug according to claim 14, wherein the dosages ensure the delivery of 10 mg/kg of body weight of ketamine, 1 mg/kg of body weight of midazolam, and 2 mg/kg of body weight of tramadol.

### Claim 16 (depends on 14, 15)

The drug according to any one of claims 14 to 15, wherein the active compound ketamine is the isomer ketamine-(S+).

### Claim 17 (depends on 4)

An association according to claim 4, characterized in that the active compounds ketamine, midazolam and tramadol are formulated in true solution for parenteral use.

### Claim 18 (depends on 4)

An association according to claim 4, characterized in that the active compound ketamine is the isomer ketamine-(S+).

### Claim 19 (depends on 5)

An association according to claim 5, characterized in that the active compound ketamine is the isomer ketamine-(S+).

### Claim 20 (depends on 17)

An association according to claim 17, characterized in that the active compound ketamine is the isomer ketamine-(S+).

### Claim 21 (depends on 13)

The composition according to claim 13, wherein the isotonizing agents is a sugar selected from the group consisting of dextrose and lactose or a polyalcohol selected from the group consisting of glycerin, propylene glycol, and polyethylene glycol.
